Trial Profile
Randomized Phase II, 2-arm Study of Immunomodulation With Atezolizumab Concomitant With High Dose Radiation (SBRT) Versus SBRT Alone in Patients With Oligometastatic Sarcomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms Stereosarc
- 22 Jul 2022 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
- 22 Jul 2022 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 05 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jul 2024.